CRISPR’s Nobel Prize sent gene-editing stocks into overdrive

Biotech stocks continued to surge on Wednesday after two scientists responsible for gene-editing tool CRISPR received this year’s Nobel Prize for Chemistry. CRISPR-powered stocks Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and Beam Therapeutics (BEAM) have now jumped 13%, 11%, and 6% respectively. CRISPR Therapeutics (CRSP), co-founded by one of the Nobel winners Emmanuelle Charpentier, is also up more than 11% since Wednesday morning. Collectively, these four CRISPR stocks are now worth nearly $12.2 billion — up from $6.5 billion in February with nearly $430 million added to their market values overnight. Now valued beyond $7.1 billion, CRSP is by far the biggest CRISPR-centric company… This story continues at The Next Web

CRISPR’s Nobel Prize sent gene-editing stocks into overdrive

Biotech stocks continued to surge on Wednesday after two scientists responsible for gene-editing tool CRISPR received this year’s Nobel Prize for Chemistry. CRISPR-powered stocks Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and Beam Therapeutics (BEAM) have now jumped 13%, 11%, and 6% respectively. CRISPR Therapeutics (CRSP), co-founded by one of the Nobel winners Emmanuelle Charpentier, is also up more than 11% since Wednesday morning. Collectively, these four CRISPR stocks are now worth nearly $12.2 billion — up from $6.5 billion in February with nearly $430 million added to their market values overnight. Now valued beyond $7.1 billion, CRSP is by far the biggest CRISPR-centric company…

This story continues at The Next Web